• Relay Medical (RELA) and Fio are pleased to report the successful deployment of its Fionet Platform at the 2021 National Bank Open Tennis presented by Rogers tournament
  • LifeLabs LP deployed the Fionet platform for testing athletes, officials, tournament employees, and other attending personnel
  • Over 2,000 antigen tests were completed with an average test result time of 15 minutes
  • Fionet Rapid Response Group, Relay and Fionet’s joint venture company, will build on this success to assist in the safe reopening of Ontario and the rest of Canada
  • The Fionet Platform is an end-to-end, rapid testing and tracking solution
  • Relay Medical is a Canadian-based technology innovator
  • Relay Medical Corp. (RELA) opened trading at C$0.24 per share

Relay Medical (RELA) and Fio are pleased to report the successful deployment of its Fionet Platform at the 2021 National Bank Open Tennis tournament.

LifeLabs LP deployed the Fionet platform for testing athletes, officials, tournament employees, and other attending personnel at the tournament.

Testing began at the Toronto site on July 31 and continued for the duration of the tournament. During the tournament, LifeLabs and the Fionet system completed over 2,000 antigen tests, with an average test result time of 15 minutes.

Charles Brown, President and CEO of LifeLabs commented on the partnership.

“We are proud of the role that LifeLabs played with our partners in safely bringing professional tennis back to Toronto. We want to congratulate the players as well as Tennis Canada on completing such a successful event. We look forward to supporting the tournament again next year.”

Fionet Rapid Response Group, Relay and Fionet’s joint venture company, will build on the success from the 2021 National Bank Open and the deployment of Fionet at Toronto’s international airport to assist in the safe reopening of Ontario and the rest of Canada.

“This was the first tournament since the pandemic lockdown. Mass testing and tracking, once seen as an obstacle to sporting events, is now practical – thanks to the use of the Fonet Platform by LifeLabs,” said Dr. Michael Greenberg, CEO, FRR.

“Fionet demonstrated its viability and potential to become a standard for large sporting events. We are grateful to Tennis Canada for the opportunity to contribute to protecting players, volunteers, and staff. Congrats to Daniil Medvedev for his inspiring play and for winning the Toronto National Bank Open Tournaments presented by Rogers.”

Fionet can be deployed into almost any location, processing at least 60 tests an hour; a solution previously available only in centralized lab facilities. Through an alliance with LifeLabs, it is integrated into LifeLabs’ laboratory information system as a turnkey, end-to-end COVID-19 rapid diagnostic testing (RDT) program for testing and real-time tracking of COVID-19 at remote and decentralized locations.

The Fionet Platform is an end-to-end, rapid testing and tracking solution for community-based or decentralized settings. 

Relay Medical is a Canadian-based technology innovator focused on the development of novel technologies in the diagnostics and AI data science sectors.

Relay Medical Corp. (RELA) opened trading at C$0.24 per share.

More From The Market Online

Cancer fighter Theralase aims to turn lab wins into human trials

Theralase (TSXV:TLT) begins Good Laboratory Practice toxicology analysis of Rutherrin, its drug candidate to target and destroy cancer cells.

Restart Life Sciences serves up exponential revenue growth

Restart Life Sciences (CSE:HEAL) more than doubled revenue at stable profit margins in Q2 2026 amid several promising commercial activations.
The Market Online Video

NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing

NurExone CEO Dr. Lior Shaltiel discusses U.S. exosome manufacturing, Mexico expansion, ExoPTEN and plans for a potential U.S. listing.
The Market Online Video

Med-X targets global pest control market with Nature-Cide

Med-X CEO Matthew Mills discusses Nature-Cide, professional pest control partnerships, global expansion and the company’s planned Nasdaq listing.